Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.31 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | DPP4 | P27487 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2434958 | 0.93 | NR1H2 (0.33) | NR1H2HSD11B1CHRM2CHRM1CHRM3 | |
| SCHEMBL12327705 | 0.91 | ITGA4 (0.33) | NR1H2CHRM2CHRM1CHRM3DPP4 | |
| SCHEMBL12327276 | 0.89 | NR1H2 (0.32) | NR1H2 | |
| SCHEMBL2438566 | 0.86 | NR1H2 (0.32) | NR1H2 | |
| SCHEMBL5358622 | 0.86 | NR1H2 (0.32) | NR1H2 | |
| SCHEMBL5358633 | 0.86 | NR1H2 (0.32) | NR1H2 | |
| SCHEMBL18462298 | 0.85 | NR1H2 (0.35) | NR1H2HSD11B1CHRM2CHRM1CHRM3 | |
| SCHEMBL27043929 | 0.85 | NR1H2 (0.37) | NR1H2HSD11B1CHRM2CHRM1CHRM3 | |
| SCHEMBL2431849 | 0.84 | DPP4 (0.31) | NR1H2DPP4 | |
| SCHEMBL2431852 | 0.84 | DPP4 (0.31) | NR1H2DPP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1346982-B1 | VLA-4 INHIBITORS | DAIICHI SEIYAKU CO (JP) | 2011-09-14 | — | — | EP | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-7157487-B2 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2007-01-02 | — | — | US | disclosed |
| US-20040110945-A1 | Vla-4 inhibitors | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2004-06-10 | — | — | US | disclosed |
| EP-1346982-A1 | VLA-4 INHIBITORS | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 2003-09-24 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110945-A1 | Vla-4 inhibitors | VCAM1, ITGA1, ITGB4 | NR1H2 533/4885HSD11B1 269/4885CHRM2 1536/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.